非神经病理医生指南:弥漫性胶质瘤的新整合分子诊断
本文综述2016年WHO中枢神经系统肿瘤分类更新中弥漫性胶质瘤的诊断变化,强调IDH、ATRX/p53和1p19q共缺失等分子参数整合诊断可更好预测生存,并指出多数IDH野生型星形细胞瘤行为类似IDH野生型胶质母细胞瘤。
要点
- IDH1/2突变是弥漫性胶质瘤分类的核心分子标志。
- 整合IDH、ATRX/p53和1p19q共缺失的诊断算法比组织学更可靠预测生存。
- 多数IDH野生型星形细胞瘤行为类似IDH野生型胶质母细胞瘤(分子GBM)。
核心结论
- 弥漫性胶质瘤诊断应向整合分子信息转变,风险分层比组织学分级更准确。
研究设计与样本
- 本文为综述,总结2016年WHO中枢神经系统肿瘤分类更新中弥漫性胶质瘤相关变化及关键基因异常。
主要发现
- IDH1和IDH2突变从根本上改变了对胶质瘤的理解和分类。
- 整合IDH、ATRX和/或p53、染色体1p19q共缺失的诊断算法结果稳健可重复,与患者生存相关性优于单独依赖常规组织学。
- 证据支持绝大多数无IDH突变的弥漫性胶质瘤(IDH野生型星形细胞瘤)行为类似IDH野生型胶质母细胞瘤(分子GBM)。
关键数值与推荐
- 诊断算法纳入IDH、ATRX和/或p53、染色体1p19q共缺失。
- IDH野生型星形细胞瘤在行为上可归为分子GBM。
临床怎么用
- 日常诊断中应结合免疫组化与靶向下一代测序面板技术检测关键分子标志。
- 采用整合分子信息的诊断路径进行风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse gliomas comprise the bulk of "brain cancer" in adults. The recent update to the 4th edition of the World Health Organization's classification of tumors of the central nervous system reflects an unprecedented change in the landscape of the diagnosis and management of diffuse gliomas that will affect all those involved in the management and care of patients. Of the recently discovered gene alterations, mutations in the Krebs cycle enzymes isocitrate dehydrogenases (IDHs) 1 and 2 have fundamentally changed the way the gliomas are understood and classified. Incorporating information on a few genetic parameters (IDH, ATRX and/or p53, and chromosome 1p19q codeletion), a relatively straightforward diagnostic algorithm has been generated with robust and reproducible results that correlate with patients' survival far better than relying on conventional histology alone. Evidence also supports the conclusion that the vast majority of diffuse gliomas without IDH mutations (IDH-wild-type astrocytomas) behave like IDH-wild-type glioblastomas ("molecular GBM"). Together, these changes reflect a big shift in the practice of diagnostic neuropathology in which tumor risk stratification aligns better with molecular information than histology/grading. The purpose of this review is to provide the readers with a brief synopsis of the changes in the 2016 World Health Organization update with an emphasis on diffuse gliomas and to summarize key gene abnormalities on which these classifications are based. Practical points involved in day-to-day diagnostic workup are also discussed, along with a comparison of the various diagnostic tests, including immunohistochemistry, with an emphasis on targeted next-generation sequencing panel technology as a future universal approach.
引用
- Lee SC. Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics. Arch Pathol Lab Med. 2018. PMID: 29775073. doi:10.5858/arpa.2017-0449-RA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。